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Abstract
The factor V Leiden (FVL) and prothrombin 20210A (PTm) mutations are associated
with single late pregnancy loss and recurrent early pregnancy loss. The prognosis
after an initial loss in womenwith thrombophilia is uncertain. Our objective was to
assess the pregnancy outcome of the second pregnancy after a first loss in women
with and without either FVL or PTm mutations. We selected women with a first preg-
nancy loss out of two family cohorts of first degree relatives of probands with FVL or
PTmmutations and a history of documented venous thromboembolism or prema-
ture atherosclerosis. Ninety-three women had had a first pregnancy loss and became
pregnant a second time. Their risk of loss of the subsequent pregnancy was higher
than in 825 women with a successful first pregnancy [25 vs. 12%, relative risk (RR)
2.0, 95% CI 1.4–3.0]. The live birth rate of the second pregnancy after an early first
loss (£ 12 weeks of gestation) was 77% (95%CI 62–87) for carriers and 76%(95% CI 57–
89) for non-carriers (RR 1.0, 95% CI 0.8–1.3). After a late first loss (> 12 weeks), the live
birth rates were 68% (95% CI 46–85) and 80% (95% CI 49–94) for carriers and non-
carriers, respectively (RR 0.9, 95% CI 0.5–1.3). In conclusion, women with a first preg-
nancy loss have a 2-fold increased risk of loss of the subsequent pregnancy,
regardless of their carrier status. More importantly, the outcome of the second preg-
nancy is rather favorable in absolute terms, even for those with thrombophilia and a
late loss, which raises concern regarding the risks and presumed benefits of antico-




Unwanted pregnancy loss is the most common gestational complication. Of all clin-
ically recognized pregnancies, 12–15% will result in a pregnancy loss.1 The actual per-
centage is believed to be even higher, because many losses remain unreported or
unrecognized. Early loss is usually defined as occurring during the first 12 weeks of
gestation, whereas late pregnancy loss concerns pregnancies that ended after a ges-
tational age of 12 weeks and implies loss of fetal heart activity on ultrasound.2 The
vast majority of pregnancy loss occurs early and only 1–2% of pregnancies are lost
after 12 weeks.3
Structural chromosomal abnormalities in either the parents or fetus and the an-
tiphospholipid antibody syndrome can be found in approximately 50% of couples
with (recurrent) pregnancy loss; in the remaining part, pregnancy loss is unex-
plained.3 Inherited thrombophilia was first associated with pregnancy loss by San-
son et al.4 in 1996 in a family study on patients with venous thrombosis and a
deficiency of one of the natural anticoagulants. The general concept is that the pres-
ence of thrombophilia together with the pregnancy itself causes a hypercoagulable
state, which may lead to thrombosis in the placental microvessels. In a meta-analy-
sis of case–control studies on inherited thrombophilia and pregnancy loss by Rey et
al.5, factor V Leiden (FVL) and the prothrombin 20210A (PTm) mutations, the most
common inherited thrombophilias, were significantly associated with recurrent early
pregnancy loss and non-recurrent late pregnancy loss (odds ratio 2.0–3.3). 
Despite these associations, there is controversy regarding the absolute risk of re-
currence in subsequent pregnancies, especially after a late pregnancy loss. The live
birth rate of the subsequent pregnancy after a late pregnancy loss was 27% in a study
by Frias et al.6 in which the presence of thrombophilia was not determined. In two
other studies, the live birth rates after a single late pregnancy loss were 11% and 23%
for carriers of either the FVL or PTm mutations and 49% and 40% for women with-
out these mutations.7,8 Contrary to these low live birth rates, Lindqvist and Merlo9 re-
cently reported that in their population-based cohort the live birth rate after a late
pregnancy loss was as high as 98% for women with a single late loss and 80% for
women with two or more late pregnancy losses. 
The actual live birth rate after a late pregnancy loss, and the question whether
thrombophilia substantially lowers this prognosis, is vital information for counsel-
ing affected women. Furthermore, it adds to the discussion about the tendency to
prescribe potentially harmful drugs that have not yet proven to be beneficial.10
In this study we set out to determine the incidence of a successful pregnancy out-
come in carriers and non-carriers of either the FVL or PTm mutations after a single
unexplained pregnancy loss. An additional objective was to ascertain if this incidence
is lower after a late pregnancy loss in the first pregnancy as compared to an early
loss.
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Materials and Methods
We previously collected a full medical history of families with various thrombophilic
abnormalities in two large multicenter studies. In the first study, we included first
degree relatives, over 14 years of age, of probands with the FVL mutation and docu-
mented venous thromboembolism (VTE).11 In the second study, we included the first
degree relatives of probands with the PTm mutation, persisting elevated levels of
clotting FVIII or mild hyperhomocysteinemia and either VTE or premature athero-
sclerosis.12-14 In this study, all participants were also tested for the presence of the
FVL mutation. All data were obtained through structured questionnaires including
detailed questions on previous pregnancies and anticoagulant use. Both studies were
approved by the Institutional Ethics Committee and written informed consent was
obtained from all study participants. 
For the present analysis we divided the female participants of these studies into
carriers and non-carriers. The carrier group consisted of all homozygotes and het-
erozygotes and compound heterozygotes of the FVL and PTmmutations. The non-
carrier group consisted of women with the wild-type gene for both mutations. 
We excluded all ectopic and terminated pregnancies and pregnancies lost because
of known chromosomal abnormalities or the HELLP syndrome. Also, pregnancies
during which anticoagulants were used were excluded, because of their potential in-
fluence on pregnancy outcome. We attempted to complete missing data regarding
pregnancy outcome, duration, and medication use by contacting the treating physi-
cian. If important missing data could not be retrieved, the concerning pregnancy was
excluded. Early pregnancy loss was defined as pregnancy loss occurring within
12 weeks of gestation based on the last menstrual period. Late pregnancy loss was
defined as occurring after 12 weeks. 
Live birth rates and concomitant 95% confidence intervals (95% CIs) were calcu-
lated by dividing the number of women with a successful pregnancy by the total num-
ber of pregnant women. The relative risk (RR) of a live birth was used to compare live
birth rates of the carrier to the non-carrier group. All data were analyzed using the
SPSS statistical software (version 11.5.2, SPSS Inc., Chicago, IL, USA) and the Confi-
dence Interval Analysis program (version 2.0, University of Southampton, UK).
Results
Of the 1512 women that were included in both studies, 1049 had had a clinically rec-
ognized pregnancy at least once. We excluded 49 women (4.7%) because all their
pregnancies met one of the exclusion criteria, and seven (0.7%) were excluded be-
cause of irretrievable missing data with regard to pregnancy outcome. Reasons for
exclusion were terminated pregnancies only (21 women; 12 carriers), ectopic preg-
nancy (one woman, non-carrier), pregnancy lost to HELLP syndrome (one woman,
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non-carrier at 40 weeks of gestation). We excluded 26 women because they used an-
ticoagulants during all pregnancies, because of VTE prior to this pregnancy. Of these,
20 women were carriers and six were non-carriers. In the end, the obstetric histories
of 993 women were analyzed; 498 were carriers of the FVL or PTm mutations, and
495 women were carriers of the wild-type genes. In the carrier group, 69% had the
FVL mutation, 24% had the PTm mutation, and 6% had both (Table 1). 75 women
(19 carriers) could not be included in the analysis of the subsequent pregnancy, be-
cause they had been pregnant just once (Figure 1). The mean age at the time of the
first pregnancy was 25.0 years (SD 3.8 years) for carriers and 25.1 years (SD 4.4 years)
for non-carriers (Table 1).
During the first pregnancy, 67 carriers had had a pregnancy loss during their first
pregnancy (13%); 46 were early pregnancy losses (9%) and 21 were late losses (4%).
In the non-carrier group, 43 women had a pregnancy loss during their first pregnancy
(9%); 33 were early losses (7%) and 10 were late losses (2%; Table 2). The live birth rate
of a first pregnancy was therefore 87% (95% CI 83–89) for the carriers and 91% (95%
CI 89–94) for the non-carriers (RR 0.9, 95% CI 0.9–1.0; Table 2). Live birth rates for
carriers of the FVL or PTm mutations were similar (87% and 84%, respectively).
93 women (58 carriers) with a pregnancy loss in their first pregnancy became preg-
nant a second time. The live birth rate of the second pregnancy in these women was
74% (95% CI 62–84) for carriers, and 77% (95% CI 61–88) for non-carriers (RR 1.0, 95%
CI 0.8–1.2; Table 3). Of the 15 women in the carrier group who had a pregnancy loss, 10
were early losses. In the non-carrier group, six out of eight pregnancy losses were
early losses. The live birth rates of the second pregnancy after a successful first preg-
nancy were 86% (95% CI 82–89) for carriers and 90% (95% CI 86–92) for non-carriers
(RR 1.0, 95% CI 0.9–1.0; Table 3). Regardless of the carrier status, the rate of pregnancy
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Age (years ± SD) 25.0 ± 3.8 25.1 ± 4.4
Factor V Leiden
Heterozygous 343 (68.9%) n.a.
Homozygous 2 (0.4%) n.a.
Prothrombin 20210A n.a.
Heterozygous 118 (23.7%) n.a.
Homozygous 4 (0.8%) n.a.
Compound heterozygous 31 (6.2%)* n.a.
*27 double heterozygous, four prothrombin mutation heterozygous and factor V Leiden homozygous;
n.a., not applicable. 
loss after a loss in the first pregnancy was 25% (95% CI 17–34%), as compared to 12%
(95% CI 10–15%) after a successful pregnancy (RR 2.0, 95% CI 1.4–3.0).
For women with an early pregnancy loss in their first pregnancy, the live birth rates
of the second pregnancy were 77% (95% CI 62–87) for carriers and 76%(95%CI 57–89)
for non-carriers (RR 1.0, 95%CI 0.8–1.3). For women with a late pregnancy loss in their
first pregnancy, the live birth rates of the second pregnancies were 68% (95% CI 46–
85) for carriers and 80% (95% CI 49–94) for non-carriers (RR 0.9, 95% CI 0.5–
1.3; Table 3). 
Three out of 15 (20%) women in the carrier group who had a pregnancy loss in their
first two pregnancies remained childless. Two had had no subsequent pregnancies,
and one had another recurrent pregnancy loss at eight weeks of gestation. In the non-
carrier group, two out of eight (25%) women with a pregnancy loss in their first two
pregnancies remained childless: one had no further pregnancies and the other had







56 without any eligible pregnancies
(40 carriers)
75 with just one pregnancy
(19 carriers)
918 pregnant
 at least twice
(479 carriers)
825 with a successful
1st pregnancy
(421 carriers) 
93 with a 1st
pregnancy loss
(58 carriers)






Figure 1. Flowchart of women studied.
Discussion
In this study we found that the chance of a successful second pregnancy in women
with either the FVL or PTm mutations is comparable to the outcome in women with-
out thesemutations. Although we found that the live birth rate in the second preg-
nancy was lower after a pregnancy loss in the first pregnancy than after a successful
first pregnancy, we did not observe a difference between carriers and non-carriers
(Table 3). However, if we analyzed data after a late pregnancy loss in the first preg-
nancy separately, the live birth rate in the second pregnancy tended to be lower for
carriers than for noncarriers (68% vs. 80%; Table 3). Unfortunately, the limited num-
ber of women with a second pregnancy after a first late loss prevents us from detect-
ing small differences, even though a 12% difference may be clinically relevant.
However, we feel that the most important observation in our study is that 74% of
women with these thrombophilias and a first pregnancy loss have a successful sec-
ond pregnancy, which is much higher than some previous reports.6-8
Women with either FVL or PTm mutations had an increased risk of pregnancy
loss in the first pregnancy as compared to non-carriers, which was accounted for by
the difference in late losses (Table 2). This is in line with metaanalyzed prior studies
on this subject.5
An important issue is the way women were selected.Women were included be-
cause they had a family or personal history of either VTE or premature atherosclero-
sis. This could introduce a selection bias, if this familial thrombotic tendency
influences the live birth rate. However, we do not think that this is the case, and this
is supported by the comparison of 184 women who eventually developed VTE after
their pregnancies to the 809 who have not developed VTE. The live birth rates of the
first pregnancies were 89.7% (95% CI 84.4–93.3) and 88.9% (95%CI 86.5–90.9), re-
spectively. We conclude that VTE is not a confounder for assessment of risk of preg-
nancy loss and that therefore no selection bias was introduced in this study.
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Table 2. Outcome of first pregnancy in carriers and non-carriers of the factor V Leiden or prothrom-
bin 20210A mutation
Carriers Non-carriers RR (95% CI)*
Number of women (n) 498 495
Pregnancy loss (n, %) 67 (13%) 43 (9%) 1.5 (1.1-2.2)
Early (n, %) 46 (9%) 33 (7%) 1.4 (0.9-2.1)
Late (n, %) 21 (4%) 10 (2%) 2.1 (1.0-4.4)
Live birth rate first pregnancy (95% CI) 87% (83-89) 91% (89-94) 0.9 (0.9-1.0)
RR, relative risk; 95% CI, 95% confidence interval; early pregnancy loss, _< 12 weeks of gestation; 
late pregnancy loss, > 12 weeks of gestation. *RR for carriers vs. non-carriers
Whether women with thrombophilia and pregnancy loss, either early, late or recur-
rent, should receive medication to improve live birth rate continues to be a matter of
debate,15,16 with some authors indicating that performing placebo controlled trials
is not ethical [17]. We disagree, and are strengthened in this opinion by the present
data and those of Lindqvist and Merlo,9 which show favorable birth rates in FVL or
PTm carriers. Although one trial found that prophylaxis with enoxaparin resulted in
a substantially better live birth rate as compared to aspirin in women with specific
forms of inherited thrombophilia and a single pregnancy loss after 10 weeks of ges-
tation,17 these results need to be confirmed and the intervention should be compared
to the current standard (i.e. no treatment or placebo).18
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Table 3. Outcome of second pregnancy in carriers and non-carriers of the factor V Leiden or pro-
thrombin 20210A mutation after a live birth or an early or late pregnancy loss in the first pregnancy.
All Carriers Non-carriers RR (95% CI)*
Live birth in the first pregnancy
Number of women (n) 825 421 404
Pregnancy loss in second pregnancy (n, %) 101 59  (14%) 42  (10%)
Early (n, %) 68 36 (9%) 32 (8%)
Late (n, %) 33 23 (5%) 10 (2%)
Live birth rate second pregnancy (95% CI) 88% (85-90) 86% (82-89) 90% (86-92) 1.0 (0.9-1.0)
Pregnancy loss in the first pregnancy
Number of women (n) 93 58 35
Pregnancy loss in second pregnancy (n, %) 23 (25%) 15 (26%) 8 (23%)
Early (n, %) 16 (17%) 10 (17%) 6 (17%)
Late (n, %) 7 (8%) 5 (9%) 2 (6%)
Live birth rate second pregnancy (95% CI) 75% (66-83) 74% (62-84) 77% (61-88) 1.0 (0.8-1.2)
Early pregnancy loss in first pregnancy
Number of women (n) 64 39 25
Pregnancy loss (n, %) 15 (23%) 9 (23%) 6 (24%)
Early (n, %) 12 (19%) 7 (18%) 5 (20%)
Late (n, %) 3 (5%) 2 (5%) 1 (4%)
Live birth rate second pregnancy (95% CI) 77% (65-85) 77% (62-87) 76% (57-89) 1.0 (0.8-1.3)
Late pregnancy loss in first pregnancy
Number of women (n) 29 19 10
Pregnancy loss (n, %) 8  (28%) 6 (32%) 2 (20%)
Early (n, %) 4 (14%) 3 (16%) 1 (10%)
Late (n, %) 4 (14%) 3 (16%) 1 (10%)
Live birth rate second pregnancy (95% CI) 72% (54-85) 68% (46-85) 80% (49-94) 0.9 (0.5-1.3)
RR, relative risk; 95% CI, 95% confidence interval; early pregnancy loss, _< 12 weeks of gestation; 
late pregnancy loss, > 12 weeks of gestation. *RR for carriers vs. non-carriers.
We conclude that the live birth rates in women with or without the FVL or PTm mu-
tations are comparable and that the success rate of the second pregnancy in women
with these mutations and a first loss is still high in absolute terms. Whether antico-
agulants are indicated for women with any form of pregnancy loss, in the presence or
even in the absence of inherited thrombophilia is unclear and should be answered in
future trials. The favorable prognosis without treatment in this study implies that a
placebo arm should be included in the design. Several such trials are ongoing (clini-
cal trial register) and should provide solid answers within the next few years. Until
then, installing anticoagulants to improve pregnancy outcome seems premature.
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